RAPT Therapeutics, Inc.
RAPTDelisted Mar 3, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001673772
RAPT Therapeutics, Inc. was delisted on Mar 3, 2026; its insiders filed their last Form 4 on Mar 5, 2026; 106 institutions reported holding it in 13F filings for Q4 2025, worth $1.02B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:54 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2025 | Mar 7, 2024 | Mar 14, 2023 | Mar 10, 2022 | Mar 11, 2021 |
| Revenue | – | $0 | $1.53M | $3.81M | $5.04M |
| Operating expenses | $136.1M | $127.1M | $87.3M | $73.0M | $58.3M |
| Research and development | $107.2M | $101.0M | $67.1M | $57.0M | $45.5M |
| Selling, general and administrative | $28.9M | $26.1M | $20.2M | $16.0M | $12.8M |
| Operating income | -$136.1M | -$127.1M | -$85.8M | -$69.2M | -$53.2M |
| Income tax | – | – | – | – | $990.0K |
| Net income | -$129.9M | -$116.8M | -$83.8M | -$69.2M | -$52.9M |
| EPS, basic | $-3.19 | $-3.05 | $-2.58 | – | – |
| EPS, diluted | $-3.19 | $-3.05 | $-2.58 | – | – |
| Weighted shares, basic | 40.8M | 38.3M | 32.5M | – | – |
| Weighted shares, diluted | 40.8M | 38.3M | 32.5M | – | – |
| Margins and growth | |||||
| Operating margin | – | – | -5618.5% | -1815.1% | -1055.4% |
| Net margin | – | – | -5490.4% | -1814.9% | -1049.0% |
| Revenue growth, year over year | – | −100.0% | −60.0% | −24.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2025 | Mar 7, 2024 | Mar 14, 2023 | Mar 10, 2022 | Mar 11, 2021 |
| Cash and equivalents | $169.7M | $47.5M | $38.9M | $24.0M | $24.9M |
| Short-term investments | $61.3M | $111.4M | $210.1M | $165.6M | $86.6M |
| Total current assets | $235.2M | $161.8M | $252.7M | $193.0M | $115.6M |
| Property, plant and equipment | $1.37M | $2.45M | $2.54M | $2.74M | $2.98M |
| Total assets | $240.3M | $173.3M | $266.2M | $198.6M | $119.0M |
| Accounts payable | $1.27M | $5.18M | $3.37M | $2.00M | $2.38M |
| Total current liabilities | $48.4M | $21.8M | $14.2M | $9.60M | $11.7M |
| Total liabilities | $50.4M | $26.3M | $21.0M | $12.3M | $14.8M |
| Shareholders' equity | $189.9M | $147.0M | $245.2M | $186.4M | $104.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2025 | Mar 7, 2024 | Mar 14, 2023 | Mar 10, 2022 | Mar 11, 2021 |
| Operating cash flow | -$83.3M | -$97.0M | -$70.8M | -$61.0M | -$40.5M |
| Capital expenditures | $122.0K | $1.13M | $845.0K | $755.0K | $398.0K |
| Free cash flow | -$83.4M | -$98.2M | -$71.6M | -$61.8M | -$40.9M |
| Depreciation and amortization | $1.20M | $1.22M | $1.05M | $996.0K | $1.12M |
| Stock-based compensation | $19.9M | $17.1M | $11.3M | $9.95M | $8.69M |
| Investing cash flow | $52.7M | $104.1M | -$45.5M | -$81.3M | -$87.4M |
| Financing cash flow | $152.9M | $1.45M | $131.2M | $141.5M | $75.5M |
| Net change in cash | $122.3M | $8.53M | $14.9M | -$891.0K | -$52.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 737.7% | 261.0% | 172.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2025 | 27.7M | −20.7% | SEC |
| Aug 1, 2025 | 16.5M | −52.6% | SEC |
| May 2, 2025 | 132.3M | +279.0% | SEC |
| Mar 3, 2025 | 132.0M | +279.4% | SEC |
| Nov 7, 2024 | 35.0M | +1.6% | SEC |
| Aug 2, 2024 | 34.9M | +1.6% | SEC |
| May 3, 2024 | 34.9M | +1.6% | SEC |
| Mar 4, 2024 | 34.8M | +1.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.